Transplant Diagnostics Market Overview
Diagnosis before transplantation is necessary to prescribe precision medicine to individual patients and to avoid graft rejection, such as T cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR).
The transplant diagnostics market on the basis of technology is categorized into nucleic acid extraction, polymerase chain reaction (PCR), next-generation sequencing (NGS), Sanger sequencing, and others. Among these, the NGS technology is projected to generate highest revenue in the coming years, owing to highly accurate results in much lesser time in comparison to other technologies.
The transplant diagnostics market based on product type is categorized into instruments, reagents, and software. The software category is expected to witness fastest growing during the forecast period, owing to the high testing efficiency and simplification of workflow in transplant diagnostics.
The transplant diagnostics market in terms of application is classified into liver transplantation, kidney transplantation, heart transplantation, and others. Among these, the liver and kidney transplantation categories are expected to generate maximum revenue in the near future. This is primarily due to the increasing number of cases of liver and kidney failure. According to the Centers for Disease Control and Prevention (CDC), in 2017, the proportion of all kidney transplant recipients was approximately 50% in the U.S.
Hospitals & clinics, academics and research centers, and the diagnostic centers are the end users in the transplant diagnostics market. Among these, the hospitals & clinics category is projected to witness fastest growth, during the forecast period. This can be primarily due to the rising number of hospitals and growing cases of liver, kidney, and heart failure.
North America held the largest share in the global transplant diagnostics market, historically. Some of the factors driving the market in the region include the presence of big market players, adoption of technologically advanced products to perform liver and renal transplants, and increasing healthcare expenditure. For instance, according to the CDC, in 2016, 19,355 patients received kidney transplants in the U.S.
Transplant Diagnostics Market Dynamics
Growing number of kidney and liver failure cases, adoption of technologically advanced products, rising healthcare expenditure, and initiatives taken by the public and private organizations in terms of investment are some of the major factors driving the transplant diagnostics market.
The scarcity of diagnostic techniques to detect the occurrence of any infection caused by transplantation is major challenge in the transplant diagnostics market. Furthermore, the unexpected technological error in the systems and inaccurate results also cause hindrance in the market.
Transplant Diagnostics Market Competitive Landscape
The key market players are actively participating in the acquisitions and product approvals or launches to gain a significant role in the transplant diagnostics market.
For instance, in June 2019, Eurofins Scientific S.E., a market player in bioanalytical testing, acquired Transplant Genomics Inc., a molecular diagnostics company committed to improving organ transplant outcomes with non-invasive serial monitoring guided by genomics. The innovative non-invasive tests for the management of patients with silent inflammation and rejection following kidney transplants are subjected to strengthen and complement the Eurofins’s transplant diagnostics offerings.
Some of the major players in the global transplant diagnostics market are F. Hoffmann-La Roche Ltd., Omixon Biocomputing Ltd., Genome Diagnostics B.V., Eurofins Scientific S.E., Thermo Fisher Scientific Inc., and bioMérieux SA.
The major countries taken into consideration for market size analysis include the U.S., Canada, France, Germany, the U.K., Italy, Spain, Russia, the Netherlands, Japan, China, India, Australia, Brazil, Mexico, Argentina, Saudi Arabia, the U.A.E., and South Africa.
